Parallel Discovery of Alzheimer’s Therapeutics

See allHide authors and affiliations

Science Translational Medicine  18 Jun 2014:
Vol. 6, Issue 241, pp. 241cm5
DOI: 10.1126/scitranslmed.3008228

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Why the government risking $1 upfront to save $39 won’t solve Alzheimer’s
    • Yuri Khodjamirian, Student - Mphil in Bioscience Enterprise, University of Cambridge

    Alzheimer’s dementia (AD) is an epidemic. 50m people live with AD globally [1]. $290bn is spent in the US on Alzheimer’s care [2], a number that could reach, in real terms, $1.35trn by 2050 [3]. Developing a disease modifying treatment has had a 100% failure rate.

    There is a desperate need for solutions, and not just scientific ones. One innovative idea proposed by Lo et al (2014) [4] (henceforth LO) is the formation of a “mega fund” to develop drugs “simultaneously”.

    In this letter I will argue there are several important shortcomings with this approach. First, I will briefly outline the arguments of the original paper and summarise my critiques. Second, I will dig deeper into each critique. Finally, I will tie this all together and conclude.
    LO key points are summarised as follows:
    (1) “Although a greater upfront investment is required, the probability of at least one success should be higher with “multiple shots on goal”, increasing the efficiency of this undertaking.” [4]
    (2) Simultaneous development will decrease timelines.
    (3) The mega fund can tap debt markets which are deeper.
    (4) Using estimates of profitability, probabilities of success and co-variance, they calculate the returns of a 64 project AD portfolio (costing $38.4bn) and find it insufficient for viability in the private sector.
    (5) Replacing the “prize” with savings by Medicare and Medicaid they find attractive returns suggesting a government-based solu...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine

Navigate This Article